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Background
It is widely accepted that the elicitation of a broadly neu-
tralizing antibody (bNAb) response will be crucial for an
effective vaccine against HIV-1. Although a handful of
bNAbs have been isolated, these antibodies recognize
epitopes on the virus that have failed to elicit bNAb
responses when incorporated into a diverse range of
immunogens. Therefore, it is of high priority to identify
new bNAbs that bind to epitopes that may be more ame-
nable to immunogen design. As a first step toward this
goal, we have recently employed high-throughput direct
functional screening to identify two new broad and
potent neutralizing antibodies, PG9 and PG16, from the
memory B cells of a clade A infected donor with broadly
neutralizing serum.
Methods
MAbs were characterized using flow cytometry, ELISA,
pseudovirus neutralization assays, alanine scanning
mutagenesis, and mixed envelope (Env) trimer analysis.
Results
PG9 and PG16 were shown to bind almost exclusively to
native trimeric Env with very little binding to recom-
binant Env preparations. Epitopes were mapped to con-
served regions of the V2 and V3 loops of gp120. Certain
N-linked glycans were found to be critical in forming the
epitope, and although neither antibody neutralized HIV-
1SF162 or HIV-1JR-FL, single point mutations in the V2 loop
of gp120 were sufficient to restore the PG9 and PG16
epitopes in both of these isolates. The preference for
trimeric HIV-1 Env was shown to be governed by gp120
subunit presentation in the context of the trimeric spike
rather cross-linking of gp120 monomers.
Conclusion
Our results show that a conserved region of V2 and V3
presented on a single gp120 unit of the HIV-1 trimer is a
novel vaccine target. Future immunogens, designed to
focus the immune response on this region, will determine
its utility in the context of a vaccine for HIV-1.
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